Literature DB >> 16334021

Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.

Mai Gu1, Sophie Ghafari, Manxu Zhao.   

Abstract

OBJECTIVE: To assess the usefulness of fluorescence in situ hybridization (FISH) for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy (FNAB) specimens. STUDY
DESIGN: All FISH performed on formalin-fixed, paraffin-embedded surgical specimens during January 2003-August 2003 at the University of California Irvine Medical Center were selected. Prior FNABs were retrieved. One cytologic slide was destained in each case. The results were compared with those obtained on histologic specimens using the paired t test.
RESULTS: FISH was performed on 41 surgical specimens of breast carcinoma. Thirteen patients had prior FNABs that were positive for adenocarcinoma. After hybridization on destained fine needle aspiration slides, no cells were found in 2 cases, and the results were not readable in 2 cases. In the remaining 9 cases, the results, expressed as the ratio of copies of the HER-2/neu gene to copies of the chromosome 17 centromere, were 5.10, 1.14, 1.21, 1.12, 0.74, 1.11, 1.21, 9.87 and 2.4. Results on the corresponding histologic specimens were 5.25, 1.05, 1.13, 1.22, 1.13, 1.12, 1.21, 9.35 and 2.61, respectively. No significant difference was found (p = 0.23).
CONCLUSION: HER-2/neu amplification status by FISH can be accurately and reliably evaluated in existing archival cytologic slides.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334021     DOI: 10.1159/000326190

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  9 in total

1.  Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.

Authors:  Laura E Moreno Luna; Benjamin Kipp; Kevin C Halling; Thomas J Sebo; Walter K Kremers; Lewis R Roberts; Emily G Barr Fritcher; Michael J Levy; Gregory J Gores
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

Review 2.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

3.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

4.  Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China.

Authors:  Zhihui Zhang; Peng Yuan; Huiqin Guo; Linlin Zhao; Jianming Ying; Mingrong Wang; Huan Zhao; Qinjing Pan; Binghe Xu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

5.  Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing.

Authors:  Shin-Nosuke Watanabe; Kazuhiro Imai; Hiroshi Nanjo; Yuki Wakamatsu; Yoshihiko Kimura; Yoshihisa Katayose; Shuichi Kamata; Kaori Terata; Eriko Takahashi; Ayano Ibonai; Ayuko Yamaguchi; Hikari Konno; Misako Yatsuyanagi; Chiaki Kudo; Shinogu Takashima; Yoichi Akagami; Ryuta Nakamura; Yusuke Sato; Satoru Motoyama; Kyoko Nomura; Yoshihiro Minamiya
Journal:  Cancer Med       Date:  2020-12-06       Impact factor: 4.452

6.  HER2 gene status in primary breast cancers and matched distant metastases.

Authors:  Coya Tapia; Spasenija Savic; Urs Wagner; René Schönegg; Hedvika Novotny; Bruno Grilli; Michelle Herzog; Audrey Devito Barascud; Inti Zlobec; Gieri Cathomas; Luigi Terracciano; Georg Feichter; Lukas Bubendorf
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

7.  Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.

Authors:  S Savic; C Tapia; B Grilli; A Rufle; M P Bihl; A de Vito Barascud; M Herzog; L Terracciano; F Baty; L Bubendorf
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

8.  HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka
Journal:  Diagn Cytopathol       Date:  2016-01-22       Impact factor: 1.582

9.  Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.

Authors:  Rieko Nishimura; Nami Okamoto; Masakazu Satou; Kenta Kojima; Shinichi Tanaka; Natsumi Yamashita
Journal:  Breast Cancer       Date:  2016-01-08       Impact factor: 4.239

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.